Clearmind Medicine (CMND) Non Operating Investment Income (2023 - 2026)
Clearmind Medicine (CMND) posted quarterly Non Operating Investment Income of -$452435.0 for Q2 2026, down 168.06% year-over-year from $664768.0 in Q2 2025, and down 223.64% quarter-over-quarter from $365926.0 in Q1 2026.
Clearmind Medicine (CMND) Non Operating Investment Income (2023 - 2026) Analysis & Trends
Clearmind Medicine's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$452435.0 for Q2 2026.
- In Q2 2026, Non Operating Investment Income fell 168.06% year-over-year to -$452435.0; the TTM figure through Apr 2026 stood at -$2.4 million (down 280.43% YoY), while the FY2025 annual figure was -$1.1 million, down 259.45% from the prior year.
- Non Operating Investment Income for Q2 2026 stood at -$452435.0, down from $365926.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $790882.0 in Q4 2024, with the low at -$2.4 million in Q4 2025.
- The 4-year median for Non Operating Investment Income is $155143.0 (2024), against an average of -$207483.0.
- Peak annual rise in Non Operating Investment Income reached 231.79% in 2025, while the deepest fall reached 409.49% in 2025.
- Clearmind Medicine's Non Operating Investment Income stood at -$2.3 million in 2023, then surged by 134.21% to $790882.0 in 2024, then slumped by 409.49% to -$2.4 million in 2025, then jumped by 81.52% to -$452435.0 in 2026.
- Business Quant data shows CMND's Non Operating Investment Income at -$452435.0 in Q2 2026, $365926.0 in Q1 2026, and -$2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | 438,021.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -452,435.00 |
| Apr 30, 2026 | -452,435.00 |
| Jan 31, 2026 | 365,926.00 |
| Jan 31, 2026 | 365,926.00 |
| Oct 31, 2025 | -2.45 Mn |
| Oct 31, 2025 | -2.45 Mn |
| Jul 31, 2025 | 139,563.00 |
| Jul 31, 2025 | 139,563.00 |
| Apr 30, 2025 | 664,768.00 |
| Apr 30, 2025 | 664,768.00 |
| Jan 31, 2025 | 514,750.00 |
| Jan 31, 2025 | 514,750.00 |
| Oct 31, 2024 | 790,882.00 |
| Oct 31, 2024 | 790,882.00 |
| Jul 31, 2024 | -643,225.00 |
| Jul 31, 2024 | -643,225.00 |
| Apr 30, 2024 | 405,002.00 |
| Apr 30, 2024 | 405,002.00 |
| Jan 31, 2024 | 155,143.00 |
| Jan 31, 2024 | 155,143.00 |